retlirafusp alfa + nab-paclitaxel + cisplatin + carboplatin

Retlirafusp alfa + nab-paclitaxel + cisplatin + carboplatin is an investigational neoadjuvant combination regimen being evaluated for the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC). The regimen consists of retlirafusp alfa, a novel biologic fusion protein, administered alongside a chemotherapy backbone of nab-paclitaxel and platinum-based agents (cisplatin or carboplatin). This combination is currently being studied in Phase II clinical trials, such as NCT07618910, often in conjunction with low-dose radiotherapy, to assess its ability to induce pathological complete response (pCR) and improve surgical outcomes in patients with ESCC. Retlirafusp alfa is likely a bifunctional fusion protein targeting immune checkpoints or cytokines, though its precise biological target has not been publicly confirmed.